iSpecimen, Inc. (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.
Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality. Clients can specify criteria such as disease state, treatment history, demographics and sample processing requirements, while the company manages regulatory compliance, informed consent documentation and quality assurances in accordance with HIPAA, FDA and international guidelines.
Founded in 2015 and headquartered in Boston, Massachusetts, iSpecimen has gradually expanded its footprint to include partnerships with specimen providers across North America and select global markets. The company leverages its proprietary technology and centralized logistics to reduce lead times and deliver specimens and data under controlled chain-of-custody conditions. Over time, iSpecimen has supported thousands of research studies spanning oncology, neurology, immunology, cardiovascular disease and infectious disease.
Under the leadership of founder and CEO Eddie Clarke, iSpecimen continues to evolve its platform by adding new specimen types, enhancing data annotation tools and forging collaborations with contract research organizations and diagnostic developers. The company’s marketplace model aims to address critical bottlenecks in translational and clinical research by making high-quality human biospecimens more accessible to investigators worldwide.
AI Generated. May Contain Errors.
